Aspirin inhibits phospholipase C.
We have shown previously that aspirin (ASA) ingestion by normal human volunteers inhibits peripheral blood monocyte phospholipase C (PLC) activities ex vivo. In order to explore further the mechanism of action of ASA, normal human monocytes and differentiated human U937 cells were treated with ASA and other salicylates. Cells preincubated with ASA were found to have decreased PLC activities. Phospholipase A2 activities were not affected by salicylates. Sodium salicylate and salicylic acid, nonacetylated relatives of ASA also inhibited PLC activity. This effect was dose and time dependent and addition of cycloheximide or actinomycin D to the preincubation mixture abrogated the inhibitory effect of salicylates on PLC. This PLC inhibitory protein induced by ASA appears distinct from lipocortin, a phospholipase A2 inhibitory protein inducible by corticosteroids.
D017302:Annexins; D001241:Aspirin / Q000494:pharmacology*; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D012459:Salicylates / Q000494:pharmacology; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors*
D017302:Annexins; D006023:Glycoproteins; D012459:Salicylates; D003609:Dactinomycin; D003513:Cycloheximide; D010738:Type C Phospholipases; D001241:Aspirin; D007213:Indomethacin